How would you treat a younger patient with relapsed mantle cell lymphoma after treatment with hyperCVAD?

In front line therapy for MCL patients, induction followed by ASCT should be the standard of care followed by rituximab maintenance and follow up for MRD.

In relapsed MCL, after anthracycline and cytrabine containing therapy, BTK inhibitors appear to be the most affective agents.

Results of a pooled a...

Agee with @Dr. First Last. The only confounder being that in some cases patients treated with R-HyperCVAD do not proceed to stem cell transplantation in first remission. In those cases you could consider salvage with another chemotherapeutic again (R-DHAP/DHAOx) to induce remission and consolidate w...